BridgeBio have demonstrably improved its development of an innovative treatment for ATTR-CM, employing the investigational drug. Early trial information suggests significant improvements for those affected from this debilitating illness. This effort represents BridgeBio's commitment to managing critical patient requirements in this heart arena. At